The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Gynecologic Oncology

• Publication date

  2007-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2007.05.030PMID 17604087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau

  2006cited by this paper
• A Fas agonist induces high levels of apoptosis in haematological malignancies.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.

  2005cited by this paper
• Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells

  2004cited by this paper
• Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif.

  2004cited by this paper
• Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.

  2004cited by this paper
• Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells*

  2003cited by this paper
• The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

  2003cited by this paper
• Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex

  2003cited by this paper
• Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells

  2003cited by this paper
• A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

  2003cited by this paper
• Protein-based therapeutic approaches targeting death receptors

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.

  2002cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Activation of caspase-8 is critical for sensitivity to cytotoxic anti-Fas antibody-induced apoptosis in human ovarian cancer cells

  2002cited by this paper
• Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs.

  2002cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

  2001cited by this paper
• Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

  2001cited by this paper
• Drug resistance does not correlate with resistance to Fas-mediated apoptosis.

  2001cited by this paper
• Apoptosis induced by death receptors.

  2000cited by this paper
• Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

  2000cited by this paper
• Fas ligand-induced apoptosis.

  1999cited by this paper
• p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

  1998cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

  1996cited by this paper
• Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions.

  1995cited by this paper
• Lethal effect of the anti-Fas antibody in mice

  1993cited by this paper
• Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.

  1992cited by this paper
• Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy

  1989influential reference
• Monoclonal antibody-mediated tumor regression by induction of apoptosis.

  1989cited by this paper

• Unfolding a death signal to treat rheumatoid arthritis

  2024cites this paper
• Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for

  2019cites this paper
• The effects of obesity-related hormones on cancer cells

  2018cites this paper
• Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex

  2015cites this paper
• Antibody ligation of CM1 on cisplatin-exposed HeLa cells induces apoptosis through reactive oxygen species-dependent Fas ligand expression.

  2014cites this paper
• Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

  2014cites this paper
• Disulfide-bridged proteins with potential for medical applications: therapeutic relevance, sample preparation and structure - function relationships

  2014cites this paper
• Antibody-based fusion proteins to target death receptors in cancer.

  2013cites this paper
• Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer

  2013cites this paper
• APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells.

  2013cites this paper
• Death receptors as targets in cancer

  2013cites this paper
• In vivo Efficacy of PAMAM-Dendrimer-Cisplatin Complexes in SKOV-3 Xenografted Balb/C Nude Mice

  2013cites this paper
• APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

  2011cites this paper
• The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.

  2010cites this paper
• Combining Radiotherapy with APO 010 in Cancer Treatment

  2009cites this paper
• Combining Radiotherapy with APO010 in Cancer Treatment

  2009cites this paper
• Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.

  2009cites this paper
• Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95‐induced apoptosis

  2009influential citation
• Combining radiotherapy with death ligands in cancer treatment : feasibility and molecular mechanisms

  2009cites this paper
• Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL

  2008influential citation
• Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression.

  2008cites this paper
• Apoptosis defects in Sézary syndrome T-cells

  2008cites this paper